… safety of vandetanib in tyrosine kinase inhibitor-naive patients with locally advanced or
metastatic RAI… Patients were randomized 1:1 to vandetanib or placebo. The primary endpoint was …

… In the randomized phase 3 trial (ZETA study), 331 patients with locally advanced or
metastatic MTC received vandetanib 300 mg/day (n = 231) or placebo (n = 100). It showed a …

… , multicenter, randomized phase III clinical trial (ZETA trial), vandetanib was approved by the
… of vandetanib in patients with locally advanced or metastatic MTC, when vandetanib was …

… , but has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is
… in our study and the protocol was designed with reference to the ZETA study of vandetanib. …

… In advanced metastatic MTC, a randomized phase III clinical … a meta-analysis of randomized
controlled trials (RCT) and … subjects: patients with locally advanced or metastatic MTC; iii) …

… in a randomized phase III trial (the ZETA trial) in patients with locally advanced or metastatic
… of MTC metastatic cases manifest a slow-going course, we believe that treatment with …

… common being well-differentiated thyroid cancer (WDTC). … established locally advanced
and/or distant stage disease or … be considerably shorter than that of vandetanib, the EXAM and …

… Quote: “Patients recruited to this multicenter phase III study were randomly assigned in a
2:1 ratio to receive oral vandetanib at a starting dose of 300 mg/d or placebo until …

… LIBRETTO-531 (NCT04211337) is a randomized phase 3 study comparing first-line … or
vandetanib. Eligible patients had kinase inhibitor-naïve progressive disease documented in the …

… were observed for lenvatinib in differentiated thyroid cancer (69%, 95… The comparison of
vandetanib and sofafenib in this meta-… can be accomplished in locally advanced DTC, surgery …